ORTX - Orchard expands Be The Match Bio collaboration ahead of Libmeldy launch

Orchard Therapeutics ([[ORTX]] +3.4%) has expanded its multi-year partnership with Be The Match BioTherapies, ahead of its European commercial launch of Libmeldy (autologous CD34+ cells encoding the ARSA gene).With the amended agreement, Be The Match BioTherapies which previously helped in cell collection for Orchard’s clinical trials is to provide comprehensive support across the commercial supply chain for Libmeldy.Also known as OTL-200, Libmeldy was approved by the European regulators for the treatment of early-onset metachromatic leukodystrophy (MLD), a rare and fatal genetic disease affecting the body’s metabolic system.

For further details see:

Orchard expands Be The Match Bio collaboration ahead of Libmeldy launch